Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were up 27.9% during trading on Friday . The company traded as high as C$0.29 and last traded at C$0.28. Approximately 1,401,717 shares traded hands during trading, an increase of 100% from the average daily volume of 700,531 shares. The stock had previously closed at C$0.22.
Hemostemix Stock Up 27.9 %
The company has a market cap of C$23.96 million, a price-to-earnings ratio of -13.75 and a beta of 0.20. The company has a fifty day simple moving average of C$0.10 and a two-hundred day simple moving average of C$0.08.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- 3 Warren Buffett Stocks to Buy Now
- Buffett’s Sale of BAC Stock: A Smart Move or Missed Opportunity?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Energy Sector Shines in 2025: 2 Stocks Leading the Charge
- Which Wall Street Analysts are the Most Accurate?
- Market Volatility Ahead? These 3 ETFs Stand Out
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
